Sernova Biotherapeutics【SVA】銘柄情報

Sernova Biotherapeutics Inc (SVA) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.13

( - )

買値

0.13

売値

0.135

出来高

0.00 日の範囲 0.00

0.12 52 週間の範囲 0.21

時価総額

49.094M

前日終値

0.13

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

$ 130,946

発行済株式数

377,642,509

配当利回り

PER

-3.81

1 株当たり利益 (EPS)

-0.04

歳入

純利益

-11.91M

Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longe... Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is based in Mississauga, Canada. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.sernova.com

本社

Mississauga, Canada

設立

Sernova Biotherapeutics Inc is listed in the Healthcare sector of the トロント証券取引所 with ticker SVA. The last closing price for Sernova Biotherapeutics was $0.13. Over the last year, Sernova Biotherapeutics shares have traded in a share price range of $ 0.12 to $ 0.21.

Sernova Biotherapeutics currently has 377,642,509 shares in issue. The market capitalisation of Sernova Biotherapeutics is $49.09 million. Sernova Biotherapeutics has a price to earnings ratio (PE ratio) of -3.81.

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the...

Sernova Biotherapeutics Announces Closing of Recently Approved Financings

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - April 23, 2026) - Sernova Biotherapeutics (TSX:...

Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - April 9, 2026) - Sernova Biotherapeutics...

Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - March 24, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC Pink: SEOVF) (FSE:...

Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - March 4, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE:...

Sernova Biotherapeutics Announces Warrant Amendments

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - February 20, 2026) - Sernova Biotherapeutics ...

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Stanford...

Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - October 1, 2025) - Sernova Biotherapeutics (T...

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB:...

Sernova Appoints Jonathan Rigby as Interim Chair

LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB:...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0.13	0.145	0.13	114462	0.13667126	CS
4	-0.02	-13.3333333333	0.15	0.17	0.12	119631	0.14964817	CS
12	-0.04	-23.5294117647	0.17	0.2	0.12	129193	0.16027215	CS
26	0	0	0.13	0.2	0.12	119860	0.15849766	CS
52	-0.02	-13.3333333333	0.15	0.21	0.12	111842	0.16069484	CS
156	-0.84	-86.5979381443	0.97	1.04	0.12	128559	0.32347723	CS
260	-1.42	-91.6129032258	1.55	1.59	0.12	126975	0.49897884	CS

SVA - Frequently Asked Questions (FAQ)

What is the current Sernova Biotherapeutics Inc share price?

The current share price of Sernova Biotherapeutics Inc is $ 0.13

How many Sernova Biotherapeutics Inc shares are in issue?

Sernova Biotherapeutics Inc has 377,642,509 shares in issue

What is the market cap of Sernova Biotherapeutics Inc?

The market capitalisation of Sernova Biotherapeutics Inc is CAD 49.09M

What is the 1 year trading range for Sernova Biotherapeutics Inc share price?

Sernova Biotherapeutics Inc has traded in the range of $ 0.12 to $ 0.21 during the past year

What is the PE ratio of Sernova Biotherapeutics Inc?

The price to earnings ratio of Sernova Biotherapeutics Inc is -3.81

What is the registered address of Sernova Biotherapeutics Inc?

The registered address for Sernova Biotherapeutics Inc is RPO Central Parkway, Mississauga, Ontario, L5A 4H2

What is the Sernova Biotherapeutics Inc website address?

The website address for Sernova Biotherapeutics Inc is www.sernova.com

Which industry sector does Sernova Biotherapeutics Inc operate in?

Sernova Biotherapeutics Inc operates in the Biotechnology & Life Sciences sector

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Sernova Biotherapeutics Inc (SVA)

Sernova Biotherapeutics Inc (SVA) 銘柄情報

個人投資家向けのプロ仕様のツール。

主要統計と詳細

Sernova Biotherapeutics Inc について

SVA 最新ニュース

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Sernova Biotherapeutics Announces Closing of Recently Approved Financings

Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders

Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing

Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval

Sernova Biotherapeutics Announces Warrant Amendments

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

Sernova Appoints Jonathan Rigby as Interim Chair

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

SVA - Frequently Asked Questions (FAQ)

SVA 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Sernova Biotherapeutics Inc (SVA)

Sernova Biotherapeutics Inc (SVA) 銘柄情報

個人投資家向けのプロ仕様のツール。

主要統計と詳細

Sernova Biotherapeutics Inc について

SVA 最新ニュース

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Sernova Biotherapeutics Announces Closing of Recently Approved Financings

Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders

Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing

Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval

Sernova Biotherapeutics Announces Warrant Amendments

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

Sernova Appoints Jonathan Rigby as Interim Chair

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

SVA - Frequently Asked Questions (FAQ)

SVA 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する